Table 1 Clinical input data used in model
Antipsychotic | Six-weekly | ||||
|---|---|---|---|---|---|
Discontinuation | Relapse |  ≥ 7% weight gain | EPS | ||
Adverse events | Other reasons | ||||
Lurasidone: adolescents (80Â mg) | 1.3% [15] | 8.8% [15] | 2.1% [17] | 5.9% [18] | 28.7% [18] |
Haloperidol (3Â mg) | 8.0% [19] | 7.5% [18] | 4.9% [20] | 9.7% [18] | 46.2% [18] |
Paliperidone (6Â mg) | 3.4% [15] | 3.8% [15] | 1.9% [17] | 14.7% [18] | 23.8% [18] |
Aripiprazole (10Â mg) | 15.3% [15] | 25.7% [15] | 4.6% [17] | 9.0% [18] | 19.5% [18] |
Lurasidone: adults (148Â mg) | 7.6% [16] | 18.2% [16] | 2.1% [17] | 5.9% [18] | 28.7% [18] |
Brexpiprazole (4Â mg) | 5.6% [16] | 25.6% [16] | 2.5% [17] | 13.5% [18] | 23.7% [18] |
Cariprazine (6Â mg) | 8.5% [16] | 28.8% [16] | 3.7% [17] | 5.6% [18] | 32.7% [18] |
Clozapine | NA | 5.4% [18] | 4.9% [21] | 33.3% [22] | 6.8% [18] |
No treatment | NA | NA | 7.1% [17] | NA | NA |